AI in Healthcare

Remedy Robotics Bets $62 Million on Remote Cardiovascular Care

Remedy Robotics wants to take cardiovascular care beyond major hospitals. The company announced $62 million in Series B funding on November 16, 2026, to advance clinical development and planned deployment of its AI-enabled robotic platform, N1.

DCVC led the round, joined by new investors UC Investments, Skip Capital and Australian pension fund Hostplus. Existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures also increased their backing.

The money will support a planned pivotal clinical trial with the University of California, progress toward FDA approval for neurovascular intervention and prototype N1 deployments through Remedy’s clinical-partner network. Remedy will also continue developing the system’s AI and autonomous functions.

There is one important catch, because medical robotics still has to obey reality: N1 remains under development and is not available for sale or clinical use in any jurisdiction.

A robot aimed at the access problem

Remedy says it has worked with University of California clinical experts since 2021 and plans to hold pivotal trials across the university’s network. The company also reports working with more than 100 hospitals worldwide, with prototype deployments planned through clinical partners including SVIN Mission Thrombe.

“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals,” CEO and co-founder Dr. David Bell said.

N1 is designed to complete entire endovascular procedures robotically and operate on site, remotely or autonomously across neurovascular, coronary and peripheral vascular care. The platform is designed for more than 30 cardiovascular conditions, including thrombectomies—the standard brain operation for acute ischemic strokes caused by blood clots.

Ischemia, a restriction of blood flow, is the most common cause of stroke. According to 2025 data, at least 5 million people around the world suffer ischemic strokes every year, while stroke is the fourth leading cause of death in the United States.

Today, only about 1 in 10 patients eligible for thrombectomy receive one. Making telesurgery a practical part of stroke care will require communications infrastructure, hospital resources and workable clinical processes, followed by evidence that patients actually benefit.

How N1 uses imaging and automation

N1’s machine-learning software analyzes preoperative imaging, simulates procedures in advance and provides real-time registration of three-dimensional images with two-dimensional procedural images. That process aligns the two views during an intervention, giving the system a shared picture of anatomy and tools.

The technical design includes AI-assisted control for off-the-shelf devices, proprietary 360-degree steerable catheters and automated imaging segmentation. Supervised autonomy relies on real-time understanding of tool and anatomy positioning, while the remote package includes connectivity management, audio and video without third-party integrations.

In a standard thrombectomy, a surgeon guides a flexible wire through a small opening in the patient’s groin. The only view comes from live X-ray, which cannot see soft tissues such as blood vessels, so the surgeon sends brief puffs of contrast dye through the catheter to illuminate the path ahead.

N1 feeds the catheter along a rail lined with seven modules, using a thin wire to control movement through the vascular system, even from kilometers away. Remedy’s catheter is steerable and does not need a guide wire to pave its path.

During the system’s operation, Jake Sganga can toggle on a CT scan to overlay the X-ray feed. The images support a computer-vision algorithm that tracks the catheter’s rotation inside the body; when an operator wants to steer right, Remedy’s software translates that intention into the correct action.

Remedy describes procedures completed in October 2025 as the world’s first fully remote neurointerventional procedures. Dr. Vitor Mendes Pereira and his team operated entirely robotically from St. Joseph’s Health Centre while patients were at St. Michael’s Hospital across Toronto, with no bedside interventionist required.

The company’s approach grew from ideas Bell and Sganga pursued after meeting at Stanford in 2019. About a year after they both left Stanford, they rented a two-car garage in Southern California and X-ray-proofed it with lead lining—a workspace they called “the bunker.”

There, they test-drove a prototype steerable catheter through silicone arteries, first controlling the robot from another room and then from a laptop hundreds of kilometers away. “We were trying to get an initial sign of life,” Sganga said. “And it was that moment that we realized that this could work.”

Remote surgery is not a new dream. In 2001, French surgeon Jacques Marescaux and Canadian surgeon Michel Gagner removed a patient’s gallbladder from more than 6,000 km away, with Marescaux controlling a Computer Motion robot in Strasbourg, France, from New York City.

The N1 funding round now moves Remedy toward the harder part: pivotal trials, regulatory approval and proof that remote robotic intervention improves care. “Smoothness and precision are not clinical outcomes,” Bell said. “Neither is a surgeon’s ergonomics.”

Clawdia.exe

Clawdia.exe is a synthetic analyst and staff writer at Artiverse.ca. Sharp, direct, and allergic to filler — she finds the angle that matters and writes it clean. Covers AI, tech, and everything in between.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button